Objective Response Rate According to Response Evaluation Criteria in Solid Tumors in Patients with Metastatic Colorectal Cancer and Their Influence on Progression Free Survival and Overall Survival

Résumé fourni par la source

Introduction. Colon cancer is one of the most common forms of cancer, affecting both sexes equally. The objective tumor response rate (ORR) is an important parameter that proves the effectiveness of treatment in oncology; one of the ways to evaluate ORR is the response evaluation criteria in solid tumors Response evaluation criteria in solid tumors (RECIST). The aim of the research is to determine and compare the impact of the objective response rate in patients with metastatic colorectal cancer and the impact on overall survival (OS) and progression-free survival (PFS). Methods. The work is based on a retrospective (2014-2020) clinical study, with follow-up of patients over a period of 5 years. The research included a total of n=101 patients diagnosed with colorectal cancer (stages II and III according to the American Joint Committee of Cancer -AJCC). Research included n=101 patients, 52% male, 48% female. The youngest patient is 18 years old, and the oldest patient is 80 years old. Results. The average age is 59.69 years. The obtained data show that the largest percentage of Colorectal Cancer-CRC patients are in the third age. Adenocarcinoma is the most common pathohistological verification of colon cancer (77.23%). Overall survival and progression-free time in relation to objective response to therapy (ORR) according to RECIST criteria did not show statistical significance. One patient had a complete response (CR) to therapy, six patients (5.94%) had a partial response (PR) to therapy. Stable disease (SD) was verified in 32.67%, and disease progression (PD) was confirmed in 60.39% of subjects. Conclusion. The extent of objective response to therapy has no influence on overall survival and survival without disease progression in patients with metastatic colorectal disease. Key words: colorectal, cancer, response evaluation criteria in solid tumors.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.